2013 Press releases
Third Quarter Results 2013
Aqualis ASA (OSE: AQUA), announces its results for the third quarter 2013, including significant post-period events.
Aqualis ASA enters the offshore market through the acquisition of Aqualis Offshore
Aqualis ASA (OSE: AQUA) has today successfully completed the acquisition of 100% of the shares in Aqualis Offshore Ltd., a specialized offshore marine and engineering consultancy group, for NOK 70 million. The acquisition has been settled though the issue of 43.75 million shares, at an issue price of NOK 1.60 per share.
Final result of the Rights Issue
Aqualis ASA (OSE: AQUA), reference is made to the stock exchange notice published on 30 October 2013 regarding the oversubscribed Rights Issue and Employee Offering. The Board of Directors of the Company has today approved the final allocation of the shares offered in the Rights Issue, which was approximately 75% oversubscribed, and the Employee Offering.
Rights Issue significantly oversubscribed
Aqualis ASA (OSE: AQUA), reference is made to the stock exchange notice published on 15 October 2013 regarding the commencement of the subscription period in the NOK 54 million Rights Issue. The subscription period for the Rights Issue and the trading period for the subscription rights expired yesterday, 29 October 2013, at 16:30 hours (CET).
Oslo Børs Approved Prospectus and commencement of Subscription Period
Aqualis ASA (OSE: AQUA), reference is made to the stock exchange notices published by Aqualis ASA (the “Company”) on 8 October 2013 and 27 September 2013 regarding minutes from the Extraordinary General Meeting and the signed final agreement to acquire Aqualis Offshore.
Appoints Chief Business Officer responsible for Healthcare activities
Aqualis ASA (formerly Clavis Pharma ASA) is pleased to announce the appointment of Ole Henrik Eriksen as Chief Business Officer, Healthcare. Mr Eriksen will be responsible for developing the Company’s pharmaceutical assets, including the current portfolio of patents and licensing agreements, as well as investigating new investment opportunities within the healthcare sector.
Company name changed to Aqualis ASA
Reference is made to the stock exchange notice of the extraordinary general meeting of Clavis Pharma ASA held on 8 October 2013, at which the general meeting resolved to change the company's name to Aqualis ASA. The new company name is now registered in the Norwegian Register of Business Enterprises.
Ex right to participate in Rights Issue today
Clavis Pharma ASA (OSE: CLAVIS), reference is made to the announcement yesterday, 8 October 2013, regarding the Minutes from the Extraordinary General Meeting and the resolved acquisition of 100% of the shares in Aqualis Offshore Ltd and the new share issue of NOK 54 million, with preemptive rights for shareholders of the Company (the “Rights Issue”).
Minutes from Extraordinary General Meeting 8 October 2013
Clavis Pharma ASA (OSE: CLAVIS), the Extraordinary General Meeting of Clavis Pharma ASA was held on 8 October 2013. Please find the minutes of the Extraordinary General Meeting attached.
Information from Election Committee
Clavis Pharma ASA (OSE: CLAVIS), reference is made to the announcement on 17 September 2013 regarding Clavis Pharma’s Extraordinary General Meeting to be held on 8 October, and agenda item 7: Election of Board. Please find attached additional information from the Election Committee in regards to this agenda item.